ClinicalTrials.gg
CompletedNCT05723822Updated Jun 5, 2023Results posted

Effects of Walkasins on Gait Speed of Individuals With Mild Cognitive Impairments

An interventional study of Walkasins in Mild Cognitive Impairment, Cognitive Decline and Gait Disorders in Old Age, sponsored by RxFunction Inc.. Completed at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by RxFunction Inc. · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,423 studies in Cognitive Dysfunction with a site in United States — 330 open to participants now, 432 under way, 13 of them phase 3. Cognitive Dysfunction · United States.

Enrollment
1,009th of 1,147
12 · median 59
Started
2023
with 117 others
No phase
716 of 1,423
182 open now
Registered
1,050th of 1,423
by date

Among the 1,423 studies in Cognitive Dysfunction with a site in United States, this one is the 1,009th largest by enrollment of the 1,147 interventional ones that give a count, is one of 118 that started in 2023, is one of 716 with no phase, and was the 1,050th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

330 of the 1,423 studies in Cognitive Dysfunction with a site in United States are open now. Recruiting first, the newest first:

325 more — sign in →

All 330 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,423 studies in Cognitive Dysfunction with a site in United States, or all of them as a file.
02

Study summary

The primary aim of this pilot study is to investigate the effect of Walkasins, a wearable lower-limb sensory prosthesis, on the gait speed and balance function of participants with mild cognitive impairment as measured by the Saint Louis University Mental Status (SLUMS) Examination.

Read the detailed description

The Walkasins system is one of a growing number of wearable devices that use various modalities of neuromodulation, defined as "the alteration of nerve activity through targeted delivery of a stimulus . . . to specific neurological sites in the body" (https://www.neuromodulation.com/). Because these technologies are relatively new, innovative applications of their use in various patient populations may lead to improvements in the care and quality of life of individuals who suffer from these life-altering diagnoses.

Previous studies of Walkasins have shown that individuals with peripheral neuropathy who have gait and balance problems walk faster with the Walkasins device. This increase may be related to an improved automaticity of gait function, which decreases the need for cognitive attention to the walking task, which is known to slow down gait. Individuals with mild cognitive impairment commonly show slow gait speeds, likely due to a decline in executive function. There is a reason to think that sensory stimuli from the Walkasins device can improve the automaticity of gait in these individuals and thereby enhance gait speed.

03

Conditions studied

  • Mild Cognitive Impairment
  • Cognitive Decline
  • Gait Disorders in Old Age
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ambulatory person who is at least 65 years of age
  • Ability to understand and provide
  • Ability to perceive vibrations from the Walkasins Haptic Module
  • Ability to complete the functional outcome measures without the use of an assistive device
  • Foot size that allows the Walkasins to function appropriately
  • Mild Cognitive Impairment (MCI) as measured by the Saint Louis University Mental Status (SLUMS) Exam (scores between 20 and 24 + or -2 for those with less than a high school education and scores between 21-26 + or -2 for those who graduated from high school, which indicate mild cognitive impairment) and/or a diagnosis of MCI (or related term) in the person's medical record
  • Slow gait speed (\<1m/second or slightly faster, provided all other criteria are met)

Exclusion criteria

Exclusion Criteria:

  • Use of ankle-foot orthosis for ambulation that prevents donning of Walkasins
  • Self-reported acute thrombophlebitis including deep vein thrombosis
  • Untreated lymphedema
  • Untreated lesion of any kind, swelling, infection, inflamed area of skin or eruptions on the lower leg near product use
  • Untreated fractures in the foot and ankle
  • Self-reported severe peripheral vascular disease
  • Other neurological conditions that impact walking (e.g., peripheral neuropathy)
  • Weighs more than 300 pounds
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Walkasins and PhySens-IMM System--Single Arm

    Participants who meet the eligibility criteria will don a pair of Walkasins and the PhySens-IMM System. They will perform some brief balance exercises (i.e., sensory integration exercises) and then complete the outcome assessments with their Walkasins turned off and without the use of an assistive device. After a rest period of about five minutes, they will repeat the outcome assessments with their Walkasins turned on.

    Device: Walkasins

Interventions

  • DeviceWalkasins

    Walkasins is a non-invasive, wearable, lower limb sensory prosthesis, prescribed by a healthcare professional for long-term daily use as a prosthesis. It directly replaces the part of the function of the sensory end organs that persons with peripheral neuropathy have lost, the sensation in the soles of their feet. The system is comprised of two primary operating components: * A Receptor Sole, properly placed in the shoe, detects and transmits plantar pressure information normally performed by the mechanoreceptors and distal axons in the soles of the feet. * A Haptic Module, worn around the lower leg, generates directional specific mechanical tactile stimuli that produce action potentials that signal relevant balance information to the nervous system.

06

What researchers measure

Primary outcomes

  1. Change in 4-Meter Gait Speed (Section 2 of the Short Physical Performance Battery)

    The 4-meter gait speed test measures the number of seconds it takes a person to walk four meters on a level surface. Gait speed measures are a significant indicator of a person's functional mobility. Higher gait speeds (meters/second) are better than lower gait speeds and are indicative of better functional mobility. (Generally, gait speeds less than 1m/second are considered slow.)

    Time frame: 3 Times During 1 Session <1.5 Hours (Screening + Walkasins Off Condition then Walkasins On Condition)

Secondary outcomes

  1. Short Physical Performance Battery (SPPB)

    The Short Physical Performance Battery measures walking speed, standing balance, and sit-to-stand performance. Scores on balance, gait speed, and chair-stand tests are added (summed) for a total score. (Scores on balance, gait speed, and chair-stand tests are not reported separately since they are not "subscales" per se.) SPPB scores may range from 0 to 12. Higher total scores indicate better balance and gait.

    Time frame: Twice During 1 Session <1.5 Hours (Walkasins Off Condition then Walkasins On Condition)

  2. Timed Up and Go (TUG)

    The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.

    Time frame: Twice During 1 Session <1.5 Hours (Walkasins Off Condition then Walkasins On Condition)

  3. Timed Up and Go Cognitive (TUG-COG)

    The TUG-COG is performed similarly to the TUG; however, the participant is also asked to count backwards by 3 from a randomly selected number between 20 and 100 while performing the TUG (standing up from the chair, walking to a line on the floor 10 feet away, turning, walking back to the chair at a normal pace, and sitting down again). Lower times indicate better/faster performance.

    Time frame: Twice During 1 Session <1.5 Hours (Walkasins Off Condition then Walkasins On Condition)

  4. Falls Efficacy Scale

    The Falls Efficacy Scale is a 16-item questionnaire that measures an individual's fear of falling or concerns about falling during activities of daily living. Scores may range from 16 (not at all concerned) to 64 (very concerned). Lower scores are better than higher scores because they indicate less concern about falling.

    Time frame: Once During 1 Session <1.5 Hours

07

Results

Posted Jun 5, 2023
Limitations and caveats
This trial was an exploratory pilot study only, and as such, participants were not randomized. In addition, 75% of the participants were females, and only 12 individuals participated in the study.

Participant flow

Participant flow — Overall Study
MilestoneWalkasins and PhySens-IMM System--Single Arm
Started12
Completed12
Not completed0

Outcome measures

PrimaryChange in 4-Meter Gait Speed (Section 2 of the Short Physical Performance Battery)

The 4-meter gait speed test measures the number of seconds it takes a person to walk four meters on a level surface. Gait speed measures are a significant indicator of a person's functional mobility. Higher gait speeds (meters/second) are better than lower gait speeds and are indicative of better functional mobility. (Generally, gait speeds less than 1m/second are considered slow.)

Time frame:
3 Times During 1 Session <1.5 Hours (Screening + Walkasins Off Condition then Walkasins On Condition)
Reported as:
Mean · Meters/Second
Change in 4-Meter Gait Speed (Section 2 of the Short Physical Performance Battery)
Meters/SecondWalkasins and PhySens-IMM System--Single Arm
Baseline Assessment for Eligibility0.79 ± 0.16
Walkasins OFF0.82 ± 0.18
Walkasins ON0.79 ± 0.20
SecondaryShort Physical Performance Battery (SPPB)

The Short Physical Performance Battery measures walking speed, standing balance, and sit-to-stand performance. Scores on balance, gait speed, and chair-stand tests are added (summed) for a total score. (Scores on balance, gait speed, and chair-stand tests are not reported separately since they are not "subscales" per se.) SPPB scores may range from 0 to 12. Higher total scores indicate better balance and gait.

Time frame:
Twice During 1 Session <1.5 Hours (Walkasins Off Condition then Walkasins On Condition)
Reported as:
Mean · Score on a Scale
Short Physical Performance Battery (SPPB)
Score on a ScaleSingle Arm
Walkasins OFF8.2 ± 1.9
.Walkasins ON7.5 ± 2.1
SecondaryTimed Up and Go (TUG)

The Timed Up and Go Test is part of the Centers for Disease Control (CDC)-recommended STEADI test protocol for balance function. From a seated position in a standard armchair, the participant is asked to stand up from the chair, walk to a line on the floor 10 feet away at normal pace, turn, walk back to the chair at normal pace, and sit down again. The tester records the time taken from the command "Go" until the subject sits down again. Lower times indicate better/faster performance.

Time frame:
Twice During 1 Session <1.5 Hours (Walkasins Off Condition then Walkasins On Condition)
Reported as:
Mean · Seconds
Timed Up and Go (TUG)
SecondsWalkasins and PhySens-IMM System--Single Arm
Walkasins OFF15.46 ± 5.4
Walkasins ON15.83 ± 5.66
SecondaryTimed Up and Go Cognitive (TUG-COG)

The TUG-COG is performed similarly to the TUG; however, the participant is also asked to count backwards by 3 from a randomly selected number between 20 and 100 while performing the TUG (standing up from the chair, walking to a line on the floor 10 feet away, turning, walking back to the chair at a normal pace, and sitting down again). Lower times indicate better/faster performance.

Time frame:
Twice During 1 Session <1.5 Hours (Walkasins Off Condition then Walkasins On Condition)
Reported as:
Mean · Seconds
Timed Up and Go Cognitive (TUG-COG)
SecondsWalkasins and PhySens-IMM System--Single Arm
Walkasins OFF21.64 ± 7.10
Walkasins ON18.85 ± 6.96
SecondaryFalls Efficacy Scale

The Falls Efficacy Scale is a 16-item questionnaire that measures an individual's fear of falling or concerns about falling during activities of daily living. Scores may range from 16 (not at all concerned) to 64 (very concerned). Lower scores are better than higher scores because they indicate less concern about falling.

Time frame:
Once During 1 Session <1.5 Hours
Reported as:
Mean · Score on a Scale
Falls Efficacy Scale
Score on a ScaleWalkasins and PhySens-IMM System--Single Arm
Falls Efficacy Scale32.2 ± 7.6

Adverse events

Collected over Adverse Events were monitored during the subject visits (lasting approximately 1.5 hours). No adverse events occurred during the study's duration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Walkasins and PhySens-IMM System--Single Arm0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Walkasins and PhySens-IMM System--Single Arm
<=18 years0
Between 18 and 65 years0
>=65 years12
Age, Continuous
Age, Continuous(Years)Walkasins and PhySens-IMM System--Single Arm
Mean84.8 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)Walkasins and PhySens-IMM System--Single Arm
Female9
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Walkasins and PhySens-IMM System--Single Arm
Hispanic or Latino0
Not Hispanic or Latino11
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Walkasins and PhySens-IMM System--Single Arm
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White11
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Walkasins and PhySens-IMM System--Single Arm
United States12
Saint Louis University Mental Status (SLUMS) Test
Saint Louis University Mental Status (SLUMS) Test(Score on a Scale)Walkasins and PhySens-IMM System--Single Arm
Mean23.5 ± 2.6
08

Study locations

1 site
  • The Pillars at Prospect Park
    Minneapolis, Minnesota 55414, United States
09

References and documents

Publications

  • Oddsson LIE, Bisson T, Cohen HS, Iloputaife I, Jacobs L, Kung D, Lipsitz LA, Manor B, McCracken P, Rumsey Y, Wrisley DM, Koehler-McNicholas SR. Extended effects of a wearable sensory prosthesis on gait, balance function and falls after 26 weeks of use in persons with peripheral neuropathy and high fall risk-The walk2Wellness trial. Front Aging Neurosci. 2022 Sep 20;14:931048. doi: 10.3389/fnagi.2022.931048. eCollection 2022. PubMed 36204554 ↗
  • Koehler-McNicholas SR, Danzl L, Cataldo AY, Oddsson LIE. Neuromodulation to improve gait and balance function using a sensory neuroprosthesis in people who report insensate feet - A randomized control cross-over study. PLoS One. 2019 Apr 30;14(4):e0216212. doi: 10.1371/journal.pone.0216212. eCollection 2019. PubMed 31039180 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Mar 2023, 1 month.

Results were first posted in Jun 2023, 2 months after primary completion.

Of 69 industry-sponsored interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 1 month is below that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2023
First posted
Feb 13, 2023
StartActual
Feb 16, 2023
Primary completionActual
Mar 31, 2023
CompletionActual
Mar 31, 2023
Results first posted
Jun 5, 2023
Last update
Jun 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05723822
Lead sponsor
RxFunction Inc.
Collaborators
Innovative Design Labs
Responsible party
Sponsor
First posted
Feb 13, 2023
Start date
Feb 16, 2023
Primary completion
Mar 31, 2023
Completion
Mar 31, 2023
Results posted
Jun 5, 2023
Last update
Jun 5, 2023

Study contacts

John P Condon, MSEE
principal investigator · Innovative Design Labs

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion